Hugel’s Botulax is comparable to the other Korean toxins from Medytox and Daewoong (the supplier of EOLS’ Jeuveau). All of these toxins are essentially the same as Botox in terms of efficacy and duration, but Botox might have better quality control (i.e. less batch to batch variation).
Hugel’s Botulax could be approved in the US in mid 2022; if so, it will compete in the aesthetic portion of the market with Botox, Jeuveau, and (eventually) the Botox biosimilar being developed by RVNC and VTRS.
News 
Market Data 
Discover 
